Heron Therapeutics (HRTX) Return on Equity: 2011-2025
Historic Return on Equity for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -0.26%.
- Heron Therapeutics' Return on Equity fell 92.00% to -0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.26%, marking a year-over-year decrease of 92.00%. This contributed to the annual value of 0.41% for FY2024, which is 1048.00% down from last year.
- Heron Therapeutics' Return on Equity amounted to -0.26% in Q3 2025, which was down 483.66% from -0.04% recorded in Q2 2025.
- Heron Therapeutics' Return on Equity's 5-year high stood at 5.43% during Q2 2023, with a 5-year trough of -582.18% in Q3 2022.
- Its 3-year average for Return on Equity is -10.73%, with a median of 0.67% in 2024.
- Per our database at Business Quant, Heron Therapeutics' Return on Equity tumbled by 58,057bps in 2022 and then skyrocketed by 58,579bps in 2023.
- Heron Therapeutics' Return on Equity (Quarterly) stood at -2.22% in 2021, then slumped by 748bps to -9.70% in 2022, then skyrocketed by 1,328bps to 3.58% in 2023, then tumbled by 327bps to 0.31% in 2024, then tumbled by 92bps to -0.26% in 2025.
- Its Return on Equity stands at -0.26% for Q3 2025, versus -0.04% for Q2 2025 and 0.12% for Q1 2025.